Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma

Authors

Dooley, Mary E. Klein

Koff, Andrew C.

Description

Summary from GEO: "Current research on CDK4/6 inhibitors (CDK4/6i) in the pre-clinical and clinical spaces are largely concerned with gaining a deeper understanding of how these drugs delay tumor growth, and how to prevent cancer cell resistance. By coordinating a first-in-kind phase II clinical trial of the CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma (DDLS) with...

Subject

Cellular Senescence

Cyclin-Dependent Kinase Inhibitor Proteins

Liposarcoma

Liposarcoma/drug therapy

RNA-Seq

Access Rights

Free to All